Retrospective Study
Copyright ©The Author(s) 2023.
World J Clin Cases. Nov 16, 2023; 11(32): 7785-7794
Published online Nov 16, 2023. doi: 10.12998/wjcc.v11.i32.7785
Table 3 Etiology, treatment, and outcome of adult-onset hypophosphatemic osteomalacia

Etiology
Onset to diagnosis (mo)
ADV dose (mg/d)
ADV duration (yr)
Medication change
Time to symptom improvement (mo)
Time to normalization of phosphate (mo)
1Tumor-induced osteomalacia25N/AN/AN/A7 d2 d
2ADV-induced nephropathy25106Keep ADV3Never
3ADV-induced nephropathy241011Change to ETV0.53.5
4ADV-induced nephropathy61010Discontinuation of ADV33
5ADV-induced nephropathy9Unknown11Change to ETV28
6Light-chain nephropathy due to multiple myeloma14N/AN/AN/A1Never
7ADV-induced nephropathy27104Change to ETV29
8ADV-induced nephropathy61107Change to TAF11